<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675724</url>
  </required_header>
  <id_info>
    <org_study_id>18-007332</org_study_id>
    <nct_id>NCT03675724</nct_id>
  </id_info>
  <brief_title>Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults</brief_title>
  <acronym>AFFIRM-LITE</acronym>
  <official_title>AFFIRM-LITE: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in
      reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug
      (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone
      resorption in elderly adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To the researchers' knowledge, there are no published studies utilizing Fisetin in alteration
      of frailty markers. Several studies involve use of Fisetin for its anti-oxidative and
      anti-apoptotic effects in animal models. Fisetin may reduce oxidative stress, alleviate
      hyperglycemia, and improve kidney function. No one has evaluated the biologic markers of
      inflammation and frailty in older adults. The researchers plan to evaluate markers of frailty
      and markers of inflammation, insulin resistance, and bone resorption while maintaining bone
      formation in older adults.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">April 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in blood inflammation markers</measure>
    <time_frame>Seven Days</time_frame>
    <description>Percent decrease in blood inflammation markers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Frail Elderly Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fisetin 20mg/kg/day, orally for 2 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules orally for 2 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fisetin</intervention_name>
    <description>Flavonoid Family</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        • Age ≥ 70 years

        Exclusion Criteria

          -  Unable or unwilling to give informed consent

          -  Pregnant

          -  Body weight &gt;150 kg or body mass index (BMI) &gt; 50

          -  QTc&gt;450 msec

          -  Total bilirubin &gt;2X upper limit of normal

          -  Inability to tolerate oral medication

          -  Abnormality in any of the screening laboratory studies (see below)

          -  Human immunodeficiency virus infection

          -  Known active hepatitis B or C infection

          -  Invasive fungal or viral infection

          -  Known hypersensitivity or allergy to fisetin

          -  Uncontrolled pleural/pericardial effusions or ascites

          -  New/active invasive cancer except non-melanoma skin cancers

          -  Subjects taking medications that are sensitive to substrates or substrates with a
             narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or
             inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are
             absolutely necessary from an infectious disease perspective, then they will be allowed
             only if the levels are therapeutic.

          -  Strong inhibitors of CYP3A4. See Appendices 1-3.

          -  Tyrosine kinase inhibitor therapy

          -  Known hypersensitivity or allergy to fisetin

          -  Subjects on quinolone antibiotic therapy for treatment or for prevention of infections
             within 10 days.

          -  Subjects taking H2-antagonists and unwilling to discontinue therapy for 1 week before
             and 2 weeks following enrollment.

          -  Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin,
             Luteolin, Dasatinib, Piperlongumine, or Navitoclax

          -  Subjects currently taking drugs that induce cellular senescence: alkylating agents,
             anthracyclines, platins, other chemotherapy

          -  Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals
             (fluconazole, miconazole, voriconazole, itraconazole), Macrolides
             (clarithromycin,erythromycin), Antivirals (nelfinavir, indinavir, saquinavir,
             ritonavir, elbasvir/grazoprevir), Rifampin

          -  Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold
             therapy 2 days prior to and during the 2-day Fisetin dosing

          -  Subjects taking the following other drugs if they cannot be held for at least 2 days
             before and during administration of Fisetin: digoxin, lithium, all statins,
             repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate,
             corticosteroids, , eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide,
             enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus,
             carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline,
             celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine,
             voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine,
             cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole

          -  In order to ensure vitamin D sufficiency, we will also exclude subjects with serum
             25-hydroxyvitamin D levels of &lt; 20 ng/ml.

          -  Presence of any condition that the Investigator believes would put the subject at risk
             or would preclude the patient from successfully completing all aspects of the trial.

        Behavioral Modification - Participants will be educated about the risk of excessive
        caffeine usage. Participants will be encouraged to reduce use by 50% prior to and during
        the 2-day drug dosing period. Due to drug-drug interaction, subjects may not clear the
        caffeine from their system properly/as usual.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Kirkland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie Volkman, RN</last_name>
    <phone>507-266-1944</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Wissler Gerdes</last_name>
    <phone>507-266-1944</phone>
    <email>wisslergerdes.erin@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammie Volkman, RN</last_name>
      <phone>507-266-1944</phone>
      <email>volkman.tammie@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Wissler Gerdes</last_name>
      <phone>507-266-1944</phone>
      <email>wisslergerdes.erin@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Kirkland, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sundeep Khosla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Elderly</keyword>
  <keyword>Aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

